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FeatureThe global prohibition of psychoactive drugs has arguably caused more 
suffering than it could ever prevent. A recent UN report shows that it also 
stimulates the creativity of those who create new designer drugs and ‘legal 
highs’. Neuroscientists have warned, on the other hand, that drugs control 
stifles research that could advance our understanding of the mind and find 
valuable therapies for mental disorders. Michael Gross reports.
Drugs prohibition is criminals’ gain, 
neuroscience’s lossHeroic invention: The company Bayer had 
great hopes for its new painkiller, heroin, at 
the beginning of the 20th century. Within two 
decades, however, its dreams turned into a 
nightmare. (Photo: Wikimedia Commons.)In August 1897, the chemist Felix 
Hoffmann created two new painkillers. 
The first, aspirin, had a lukewarm 
reception from his company at first, 
but the second one, a chemical 
modification of morphine, was soon 
produced in large quantities and 
promoted enthusiastically.
At the dawn of the 20th century, 
doctors prescribed it for nearly every 
illness under the sun, including 
depression, bronchitis, asthma, 
and coughs. Mountaineers used 
it in preparation for their climbing 
tours, and psychiatrists gave it to 
their patients. To honour Hoffmann’s 
heroic invention, Bayer called it 
heroin. Little did the company bosses 
know what the future held for their 
heroic product.
After 1910, morphine addicts in 
the US started switching to the new 
drug, in the 1920s the wave of misuse 
reached Europe, and by 1931 the 
control laws had been tightened so 
much that Hoffmann’s heroin was 
practically dead as a medical drug — 
much to the disadvantage of patients, 
as it really does have significant 
benefits as a strong painkiller.
So what went wrong and how 
could Bayer’s big hope turn into 
such a disaster? It was simply a 
question of how people use the 
drug. Patients can safely swallow 
a couple of milligrams, as there 
is no risk of getting addicted to 
it, and there is no rapturous high 
either. It is just a painkiller. Heroin 
junkies use around ten times more 
and they inject it, leading to a more 
dramatic effect, as the whole dose 
overwhelms the brain at once. Even 
then, clean heroin isn’t nearly as 
dangerous as the record of fatalities 
suggests. Most of the dangers of 
street heroin arise from impurities, 
deliberate stretching, and non-sterile 
needles. Heroin, like many other inventions, 
is a dual-use technology. The 
molecule by itself is neither good nor 
bad, but it can be helpful or harmful 
depending on what people do with it, 
and also how authorities manage the 
use and misuse.
Losing the war on drugs 
Tight control laws based on three UN 
treaties from 1961, 1971 and 1988 
have failed to curb the global demand 
and supply of drugs. Essentially, 
they have had two main effects on 
the drugs market: pushing the trade 
underground, and encouraging 
people to look for new kinds of drugs 
that enjoy a brief fame as ‘legal 
highs’ until they, too, get banned.
In 2009, the magazine The 
Economist, quite far from any 
suspicions of hippie sympathies 
or dope-headedness, ran a major 
story on the 100th anniversary of 
the Shanghai Opium Commission 
(the first international conference on 
drugs) and concluded unequivocally 
that the global war on drugs is 
unwinnable. The incarceration of 
hundreds of thousands of young 
people who have committed no crime 
other than possessing cannabis, 
the unimaginably cruel gang wars 
along the smugglers’ route through 
Central America, the death sentences 
handed to alleged drug mules in 
Asian countries, and the unshakably 
constant levels of drugs supply and 
demand all suggest that prohibition 
is doing more harm than good. This 
conclusion shouldn’t surprise anyone 
who has considered the precedent 
of alcohol prohibition in the US from 
1920 to 1933.
Nevertheless, the most recent 
world drug report from the United 
Nations Office on Drugs and Crime 
(UNODC), published in June 2013, 
insists on carrying on as before, even though the figures within the report 
show that drug use has remained 
stable compared with the previous 
data from 2009.
What has changed since 2009 is 
that the invention of new legal highs 
is now a booming business, to which 
roughly half of the length of the report 
is dedicated. The report finds that the 
number of new, still legal substances 
now exceeds the number of drugs 
banned under international drug 
treaties. The UNODC report bundles 
as ‘New Psychoactive Substances’ 
(NPS) all those that emerged onto 
the international market after the 
1971 convention, even though some 
of them have been used for much 
longer. 
The report finds: “The emergence 
of new substances in the drug 
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Green shoots: The cannabis plant (Cannabis 
sativa) can look back on millennia of useful-
ness to mankind, from hemp fibres used in 
the Gutenberg bible through to medications 
given to Queen Victoria. Its criminalisation 
under global drug treaties induces people 
to try alternatives that aren’t banned yet, but 
may be more dangerous. (Photo: © GW Phar-
maceuticals.)markets has clearly gained pace over 
the last decade: 251 NPS had been 
identified by Member States as of 
mid-2012.” By the time the report 
was released, this figure had risen to 
over 300.
The product spectrum shifts 
quickly, both with fashion, and in 
response to attempts at blocking 
new substances. Current favourites 
include ‘Spice’ products (i.e. 
synthetic cannabinoids sprayed 
onto other herbs) and ‘bath salts’ 
containing synthetic cathinones 
(variants of the active ingredient 
of the khat plant). Synthetic 
cannabinoids alone accounted for a 
quarter of the substances reported, 
demonstrating that the market is 
driven by the desire to sidestep the 
prohibition of cannabis.
“Most of these drugs act as stand-
ins for MDMA (more commonly 
known as ecstasy), cannabis, 
LSD and mushrooms containing 
psilocybin (commonly known as 
magic mushrooms). The latter three 
drugs have no recorded cases of 
toxicological fatalities,” observes 
author Mike Power in a comment 
for The Guardian. Power, who has published a book on the internet drug 
trade (Drugs 2.0: The Web Revolution 
That’s Changing How the World Gets 
High), concludes that public health 
would be best served if the relatively 
safe substances like cannabis and 
magic mushrooms were legalised 
and put under official quality control. 
If people were allowed to smoke 
cannabis, there would be no demand 
for a confusing variety of new and 
untested cannabinoid products.
Apart from newly synthesized 
substances, the NPS category also 
includes a few traditional plant-based 
materials with regional popularity, 
such as the herbal stimulant khat 
(also known as qat) in Yemen and 
the Horn of Africa.  Several European 
countries have banned khat, but the 
UK government’s Advisory Council 
on the Misuse of Drugs (ACMD) 
published a review in February 2013 
concluding that there was insufficient 
evidence of it causing any harm. 
Nevertheless, the home secretary 
Theresa May announced on July 3rd 
that the herb is going to be banned 
in the UK, ignoring the advice of the 
expert body. Former ACMD chair 
David Nutt ridiculed the decision 
in a comment for The Guardian 
newspaper published the same day, 
writing it would make just as much 
sense to ban cats.
The UNODC report acknowledges 
that it is impractical to include an 
ever more rapidly growing number of 
new substances in new international 
control strategies, but doesn’t admit 
that prohibition itself is the root cause 
of this proliferation, as Power has 
pointed out.
Several countries have introduced 
new control measures to respond 
quickly to new substances emerging. 
In the UK, the Netherlands and 
Germany, ministers can ban a 
substance for a year, to allow the 
legislator time to classify them. 
Similarly, the US has ordered 
preliminary scheduling for several 
synthetic cannabinoids and synthetic 
cathinones before putting them under 
permanent control regulations.
 Regarding the various attempts by 
some countries to put a lid on new 
substances, the report concludes: 
“While all of these approaches 
have pros and cons, they are all 
valuable experiments.” However, it 
also cautions that it is too early to 
see which, if any, of these individual 
approaches works.Censoring neuroscience
Apart from the futility and the human 
cost of drugs prohibition, there is a 
third reason to reconsider the policy. 
A growing number of neuroscientists 
argue that legal restrictions on 
mind-altering drugs are stopping 
them both from gaining a better 
understanding of the brain and from 
developing new therapies for mental 
disorders.
In a recent paper, David Nutt from 
Imperial College, together with Leslie 
King, formerly at the UK’s Forensic 
Science Service, and David Nichols 
of the University of North Carolina 
argued this case in some detail (Nat. 
Rev. Neurosci. (2013) http://dx.doi.
org/10.1038/nrn3530).
First, they reiterate the known 
flaws of the current drugs legislation. 
“The decisions that were made 
about which drugs should be 
controlled under this legislation 
seem to be unclear and inconsistent 
and may have been made for 
political rather than health-related 
reasons,” the authors write. In 
previous publications, Nutt and 
others had shown that there is little 
or no relation between the legal 
classification of substances and their 
actual danger. Nutt famously stated 
that in terms of fatalities per time 
spent on a recreational activity, horse 
riding is more dangerous than taking 
an ecstasy pill on a night out. Rather 
than adjusting the policy to the 
evidence, the then home secretary of 
the UK, Alan Johnson, responded by 
forcing Nutt to resign from his post 
as chairman of the ACMD in 2009.
One argument often used in drug 
classification is the lack of medical 
use. However, the authors argue, 
“once a drug is classified under 
Schedule 1, it is unlikely that any 
medical value will ever be discovered 
for it, because it is extremely difficult 
to research the drug. The argument 
[…] thus becomes circular.”
The barriers preventing research 
on Schedule 1 drugs are significant. 
Each institution has to apply for a 
special licence to deal with such 
drugs, and install extra levels of 
security to prevent misuse. Even 
researchers handling minute 
amounts, less than a single dose 
a drug user would take, have to 
follow procedures to account for the 
whereabouts of that amount. In the 
UK, the authors say, there are only 
three hospitals that have this special 
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Pain relief: Sativex™ is a cannabis-based prescription drug developed by GW Pharmaceuti-
cals in the UK and licensed for treatment of pain and spasticity in multiple sclerosis. (Photo: © 
GW Pharmaceuticals.)licence and can handle cannabis 
or MDMA (ecstasy). Ironically, all 
UK hospitals are allowed to handle 
opioids, including heroin, which is 
only classified as Schedule 2 in the 
UK, even though its abuse is a much 
greater worry than that of cannabis 
or ecstasy.
To make matters worse, funding 
agencies and ethics committees 
generally shy away from approving 
any research projects involving such 
drugs, on the false assumption that 
these must be very dangerous. Only 
a few organisations, typically those 
specialising on such issues, fund 
research with such drugs. These 
include the Beckley Foundation, 
the Heffter Research Institute, and 
the Multidisciplinary Association for 
Psychedelic Studies (MAPS).
Nutt and colleagues argue that 
this situation severely inhibits 
progress in neuroscience. After all, it 
is no coincidence that these much-
maligned substances have profound 
influence on the mind. They do so, 
because they interact with specific 
receptors that are important for our 
brain function, and thus studies 
of their mechanisms could reveal 
important details.
For instance, cannabis has an 
effect on us because the body 
uses similar substances, the 
endocannabinoids, as molecular 
messengers. One class of 
endocannabinoid receptors, the 
authors say, is the most densely 
expressed group of G-protein 
coupled receptors in the human 
body. And yet, research papers on 
the function of these receptors are 
sparse because of the legal barriers 
inhibiting this research.
One UK company, GW 
Pharmaceuticals, managed to 
bypass all these hurdles and 
obtain a licence for Sativex™, 
an alcoholic solution of THC and 
other cannabinoids, which can 
be prescribed for the treatment 
of pain and spasticity in multiple 
sclerosis. Even though this clearly 
demonstrates medical usefulness of 
cannabis, it did not lead to abolition 
of its Schedule 1 status.
Similarly, there are known medical 
uses for MDMA (ecstasy), which 
was first used in the US to facilitate 
psychotherapy, as it enabled people 
to open up and communicate better. 
It was also found beneficial in a 
small clinical trial of patients with post-traumatic stress disorder. 
Specifically, MDMA makes it easier 
for patients to relive the trauma and 
thereby overcome it, which is part of 
the currently accepted therapy, but 
would in some very severe cases be 
unbearable for patients without the 
drug.
Psychedelics, such as LSD, with 
their mind-altering activity have long 
been seen as immensely interesting 
scientific tools for the study of mind 
and consciousness. This was also 
the view of the discoverer of LSD, 
Albert Hofmann, who never saw his 
‘problem child’ as a recreational 
drug. As he lived to the age of 102, 
his own experiments with his drug 
seem to have had no ill effect.
In the 1950s and 60s, there was a 
vibrant research field studying the 
effects of LSD on the brain, which all 
but disappeared after the substance 
was banned. It was unfortunate 
timing that this ban struck it down 
before the emergence of brain 
imaging techniques that could have 
revealed what actually happens 
in a brain on an LSD trip. As the 
perceptions and consciousness of 
people under its influence are so 
drastically different from their sober 
selves, many scientists think that 
such research could have revealed 
quite a lot about the inner workings 
of our minds.In fundamental neuroscience, 
psychedelics are valuable as they are 
agonists of the serotonin receptor 
5-HT2A, which is highly expressed 
in a group of neurons in the cortex 
thought to be involved in top-down 
processing of sensations and 
emotions, and which may be affected 
in conditions including schizophrenia 
and depression.
Since the paper appeared, Nutt 
says, “we have discovered the recent 
banning under a TBO [Temporary 
Banning Order] of many chemicals 
in the NBOMe series means the only 
PET [positron emission tomography] 
tracer for the agonist state of the 
5-HT receptor is now illegal!” The UK 
government banned the psychedelic 
NBOMe and the amphetamine-
mimicking stimulant Benzo Fury 
with effect from June 10th for 12 
months, while the ACMD prepares an 
assessment.
Psychedelics are also of interest 
for clinical applications. LSD was 
investigated (before the ban) as a 
tool for psychotherapy as well as to 
treat alcohol addiction. After the ban, 
these clinical studies moved on to 
legal substances, such as psilocybin 
(from magic mushrooms), which in its 
turn was banned in the UK in 2005.
Psychedelics have also shown 
promise for treatment of obsessive 
compulsive disorder (OCD) and 
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Psychedelic molecule: Albert Hofmann, the inventor and first user of LSD, with a model of 
the molecule he called his ‘problem child’. Far from seeing it as a recreational drug, Hofmann 
hoped that it would enable people to gain a deeper understanding of consciousness and spir-
ituality. (Photo: istockphoto.com.)
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Catherine Tallon-Baudry is a CNRS 
senior researcher in Cognitive 
Neuroscience at the Ecole Normale 
Supérieure in Paris. She earned her 
PhD in Neuroscience in Lyon in 1997, 
working with Olivier Bertrand. She 
was a post-doctoral Marie-Curie 
fellow in Andreas Kreiter’s laboratory 
in Bremen, Germany, before coming 
back to Lyon with a tenured position. 
In 2002, she moved to the Pitié-
Salpêtrière Hospital in Paris to 
form her own research group. In 
2012, she moved her group to the 
Ecole Normale Supérieure in Paris. 
She is a vision scientist, aiming to 
understand the neural mechanisms 
behind humans’ amazing ability 
at deriving meaning from visual 
information — from Gestalt 
perception to visual consciousness. 
She is an electrophysiologist at heart, 
fascinated by the rich complexity of 
brain dynamics. She did some early 
grid electrocardiographic recordings 
in monkeys, but mostly worked with 
humans, using MEG and EEG in 
healthy participants and intracranial 
EEG in epileptic patients, pioneering 
the field of induced gamma-band 
oscillations in humans.
What turned you on to biology 
in the first place? As a kid I was 
not particularly interested in any 
aspect of science, except maybe 
paleontology; it took me a while to 
grow out of my prehistoric days. 
When I was thirteen I stumbled 
upon an article on the brain and 
thoughts in a lay-audience magazine. 
This came as a revelation: one 
could actually study the processes 
through which thoughts develop 
and try to understand why we are 
so well equipped to make sense of 
everything. At the stage when I was 
then wondering whether I should 
study biology, medicine, philosophy 
or psychology to get into this field, 
I went to visit a neuroscience lab. 
I discovered there a new species — 
the researcher! I was hooked, and 
though I understood probably less 
than 5% of what was being explained 
to me, I was sure that the lab was 
Q & Aof cluster headaches, a severe 
condition with few other treatment 
options and a significant suicide risk.
“This hindering of research and 
therapy is motivated by politics, 
not science. It’s one of the most 
scandalous examples of scientific 
censorship in modern times,” said 
Nutt in a press statement.
What’s to be done?
Changing the international 
classifications enshrined in UN 
schedules would be difficult, 
suggests Nutt, but there are things 
that individual governments could 
do to help neuroscience, such as 
giving hospitals a general permission 
to use banned substances, the same 
way as UK hospitals are already 
allowed to use heroin.
Amanda Feilding, founder and 
director of the Beckley Foundation 
which supports research into 
psychoactive substances, is more 
optimistic about the chance to turn 
global drugs policies around. “The 
past two months have been an 
incredibly busy and productive time 
for global drug policy reform and 
scientific research into psychedelic 
drugs. Never in my 15 years as 
director of the Beckley Foundation 
have I seen such rapid progress in these complementary fields,” 
Feilding wrote in an opinion piece 
published by The Guardian in June.
Feilding is particularly 
encouraged by a shift of attitudes 
in Latin America, where she acts 
as an advisor for the President 
of Guatemala. “There is near-
unanimous agreement in Latin 
America that the ‘war on drugs’ 
has failed, with leaders becoming 
increasingly vocal in their 
determination to push the reset 
button,” Feilding wrote.
Even in the US, Feilding says, 
prohibition is beginning to fall apart, 
as 19 states now allow possession 
of cannabis and secretary of state 
John Kerry has said that efforts 
must focus on the treatment of 
users and on education rather than 
incarceration.
If politics can really turn around 
and discuss drugs problems 
rationally and based on the scientific 
evidence, there is hope that the 
balance of their dual nature can 
be shifted, so that we can limit the 
damage and reap the benefits of 
psychoactive substances.
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